Breast Cancer Liquid Biopsy Market
Report code - SRHL125 | Published On : NA | Status: Upcoming

Opportunities & gaps in The Global Breast Cancer Liquid Biopsy Market by Epidemiology, Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Others), Product (Equipment, Assay Kits), End-User (Hospital Laboratories and Advanced Reference Laboratories) and by Region (North America, Western Europe, Asia-Pacific, Rest of the World)

This report, from Stratview Research, studies The Global Breast Cancer Liquid Biopsy Market over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.

The Burning Questions This Report Will Answer:

  1. Over 1.5 million people worldwide die from lung cancer per year; why does the disease still has an extremely poor prognosis with all the modern technology?
  2. What are the options available for accurate prediction of lung cancer?
  3. Which market is more lucrative pharma, diagnostics or surgery?
  4. Which technologies are available currently and how will the future technologies disrupt the market?

The Global Breast Cancer Liquid Biopsy Market: Highlights

Oncologists believe that monitoring and therapy selection of metastatic breast cancers shall be the major focus for the next few years and hence attractive. However, from the point of view of a market stakeholder this segment is highly crowded and competitive. So how does each stakeholder make money and sustain their market share?

According to JP Morgan analysis, this segment could be worth $2bn a year by 2020. In the next 2-3 years, liquid biopsy technology will also come to be used for predicting the likely course and outcome of disease for individual patients. Improved patient experience from a non-invasive approach to molecular profiling of a tumor compared with tissue biopsy, especially for patients who require serial biopsies are the few factors that are likely to drive this market in the US, Europe and APAC.

One of the key challenges to uptake of liquid biopsy is the cost of actual sequencing: at present, it is only possible to obtain an adequate depth of sequencing at a cost that is too expensive for routine clinical use. The report looks at the positive side of this market as well as the possible hurdles which can make the stakeholders re-strategize their plans again and again in the developed and developing markets.

The report also looks at the opportunity geography wise hence giving a 360 degree view of the market, its opportunities and gaps for the reader.

Research Methodology

Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

  • Market structure: Overview, industry life cycle analysis, supply chain analysis
  • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
  • Market trend and forecast analysis
  • Market segment trend and forecast
  • Competitive landscape and dynamics: Market share, Product portfolio, New product launches, etc.
  • Attractive market segments and associated growth opportunities
  • Emerging trends
  • Strategic growth opportunities for the existing and new players
  • Key success factors 
  • Future outlook

The Global Breast Cancer Liquid Biopsy Market is segmented into the following categories: 

By Epidemiology

By Circulating Biomarkers

-Circulating Tumor Cells

-Circulating Tumor DNA

-Others

By Product

-Equipment

-Assay Kits

By End User Location

- Hospital Laboratories

- Advanced Reference Laboratories

By Region

  • North America (Country Analysis: the USA, Canada)
  • Western Europe (Country Analysis: Germany, France, the UK)
  • Asia-Pacific (Country Analysis: China, Japan, India, and Rest of Asia-Pacific)
  • Rest of the World (Sub-Region Analysis: The Middle East, Africa, Rest of Europe and Others) 

Report Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our first-time clients:

Company Profiling

  • SWOT analysis of key players (up to 3 players)
  • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview research offers custom research services across sectors. In the case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.




By clicking Submit button you accept our terms and conditions


Related Reports




Looking for Customized Report?

By clicking Submit button you accept our terms and conditions

Our Clients

Call Us : +1-313-307-4176